Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...
A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer. At Novartis Biomedical Research, oncology teams around the ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix ...
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...
About Novartis in Cardiovascular Disease At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud ...
Imagine stepping into a space where cutting-edge technology meets life-changing impact. At Novartis we’re building something extraordinary – an Innovation Lab (iLab) where we are mastering the art and ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused ...
One of the secrets to living a longer, better life is beating in our chests. An estimated 80% of cardiovascular disease (CVD) can be prevented with lifestyle changes and available tools, yet it ...
The Novartis HIT team is composed of experienced technical subject matter experts. These informaticists specialize in patient-centered care and HIT optimization coordination. The HIT Team can offer ...
At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results